||Awaiting full HTA submission from Applicant
||Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of icosapent ethyl compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant